Roche Holding AG

Type: Company
Name: Roche Holding AG (Roche Holding Ltd)
Nationality: Switzerland
Web Address: http://www.roche.com/
Fact Sheet: Fact Sheet for Roche Holding AG
First reported 1 hour ago - Updated 1 hour ago - 1 reports

Reports from F. Hoffmann-La Roche Highlight Recent Findings in Economic Dynamics (Genotoxicity profile of azidothymidine in vitro)

By a News Reporter-Staff News Editor at Economics Week -- Research findings on Economic Dynamics are discussed in a new report. According to news reporting originating in Basel, Switzerland , by VerticalNews journalists, research stated, "Azidothymidine ... [Published 4 Traders - 1 hour ago]
First reported 7 hours ago - Updated 2 hours ago - 1 reports

Puma Biotech up more than 270% in one day

A biotech firm you may not have heard of, Puma Biotechnology (PBYIPuma’s stock more than tripled afterPuma Biotechnology said their drug, neratinib was given to 2,821 patients with early-stage breast cancer whose tumor growth was fueled by a gene called ... [Published Yahoo! News - 7 hours ago]
First reported 5 hours ago - Updated 5 hours ago - 1 reports

Reports Outline Clinical Trials and Studies Study Findings from F. Hoffmann-La Roche (A randomized, placebo-controlled study investigating the...

Reports Outline Clinical Trials and Studies Study Findings from F. Hoffmann-La Roche (A randomized, placebo-controlled study investigating the nicotinic ?7 agonist, RG3487, for cognitive deficits in schizophrenia)By a News Reporter-Staff News Editor at ... [Published 4 Traders - 5 hours ago]
First reported 14 hours ago - Updated 6 hours ago - 2 reports

Branded and Targeted Treatments Driving Almost $4 Billion Growth in Breast Cancer Therapeutics Market by 2020, says GBI Research

NEW YORK (GBI Research), 22 July 2014 - The increased use of targeted therapies, along with a greater uptake of branded drugs and rising incidence population, will cause the breast cancer therapeutics market value to grow from $9.2 billion in 2013 to ... [Published Samedan Ltd Pharmaceutical Publishers - 11 hours ago]
First reported 14 hours ago - Updated 9 hours ago - 1 reports

Melanoma combination therapy study shows promising results

Genentech has announced that its phase 3 coBRIM study, evaluating the safety and efficacy of a combination of cobimetinib and vemurafenib for the treatment of melanoma, has met its primary endpoint.Genentech, a Roche company, studied the combination in ... [Published Dermatology Times - 14 hours ago]
First reported 10 hours ago - Updated 10 hours ago - 1 reports

S&P rises to record, stocks mixed on earnings

—By CNBC's Kate Gibson and Evelyn ChengComing Up This Week:WednesdayEarnings: AT&T , Facebook , Gilead Sciences , Qualcomm , Citrix , ETrade , Equifax , Varian Medical , Weatherford International , Omnicare , Praxair , Biogen Idec , Ryder Systems , Raymond ... [Published CNBC - 10 hours ago]
First reported 11 hours ago - Updated 11 hours ago - 1 reports

Fury over West Wallsend tyre dumping

MORE than 300 tyres have been dumped on West Wallsend land earmarked for conservation, infuriating residents and the landowner. MORE than 300 tyres have been dumped on West Wallsend land earmarked for conservation, infuriating residents and the landowner. ... [Published Newcastle Herald - 11 hours ago]
First reported 16 hours ago - Updated 16 hours ago - 1 reports

MicroRNA Market: Diagnostic and Therapeutic Research 2019

Micro-RNA is a small non-coding RNA molecule which is a vital component of genetic regulation. Set of micro-RNAs are present in plants and animals functioning in gene expression process. They are involved in the normal functioning of the eukaryotic cells. ... [Published MyNewsDesk - 16 hours ago]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

Roche Earnings Preview: Continued Adoption For Key Cancer Drugs Will Drive Growth (July 24th, publish today or tomorrow)

Roche Holdings (OTC:RHHBY) will report its Q2 2014 results on July 24th. We expect mid single digit growth for its pharmaceutical business assuming that the overall currency impact remained minimal.  Additionally, we expect continued strong growth in ... [Published Trefis - Jul 22 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 4 reports

FDA fast-tracks Roche's Avastin for tough-to-treat ovarian cancer

Last week, it was priority review for cervical cancer. This week, it's the fast track for difficult-to-treat ovarian cancer. That's the record for Roche's ($RHHBY) Avastin, which is now up for quick FDA approval of two new indications.The potential nod ... [Published FiercePharma - Jul 22 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 2 reports

European shares up as Ukraine rebels allow improved access

* FTSEurofirst 300 index gains 0.9 percent* Ukraine rebels hand over black boxes from Malaysian plane* ARM Holdings surges after strong results* Actelion gains as results revive M&A speculationLONDON, July 22 (Reuters) - European equities bounced back ... [Published CNBC - Jul 22 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 2 reports

ROCHE BEARER SHARE : FDA grants Roche's Avastin Priority Review for recurrent platinum-resistant ovarian cancer

FDA grants Roche's Avastin Priority Review for recurrent platinum-resistant ovarian cancerRoche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application ... [Published 4 Traders - Jul 22 2014]

Quotes

According to the news reporters, the research concluded: "Increased micronucleus frequency is likely related to nucleotide pool imbalance."
"These results demonstrate that NRTIs retain sufficient activity even after first-line failure to be retained in subsequent regimens, provided a boosted PI is included. The inadequate performance of the boosted PI monotherapy arm should probably put an end to this treatment approach for most patients" Paul E Sax, MD, told Medscape Medical News
"Overall a really good call with no new disclosures that diluted the quality of the EPS/sales beat on the quarter" he wrote in an email to clients after the conference call
According to the news editors, the research concluded: "In patients with stable schizophrenia, RG3487 did not improve cognitive deficits, as assessed by the MCCB; however, in patients with moderate negative symptoms, a post hoc analysis revealed significant improvement of negative symptoms."

More Content

All (1618) | News (1364) | Reports (1) | Blogs (203) | Audio/Video (1) | Fact Sheets (27) | Press Releases (20)
sort by: Date | Relevance
Glaxo’s Witty Has Bigger Problem Than China as ... [Published Washington Post - 1 hour ago]
Reports from F. Hoffmann-La Roche Highlight Rec... [Published 4 Traders - 1 hour ago]
Is Gilead About to Crush Pharmacyclics Stock? [Published Motley Fool Discussion Boards - 1 hour ago]
Raltegravir Not Better Than NRTIs for Refractor... [Published Diabetes Care - 2 hours ago]
Federally Funded Trials Praised—and Underfunded [Published The ASCO Post - 2 hours ago]
Is Inovio Undervalued After Positive HPV Therap... [Published Seeking Alpha - 3 hours ago]
Investigational Immunotherapy Demonstrates Resp... [Published The ASCO Post - 3 hours ago]
Biogen Idec Beats And Raises: Reassessing Its P... [Published Seeking Alpha - 4 hours ago]
Puma Biotech Soars on Positive Breast Cancer Dr... [Published Washington Post - 4 hours ago]
What to Watch in The Day Ahead; Thursday, July 24 [Published Reuters - 5 hours ago]
Reports Outline Clinical Trials and Studies Stu... [Published 4 Traders - 5 hours ago]
UPDATE 1-U.S. FDA approves Gilead blood cancer ... [Published CNBC - 5 hours ago]
Report: Over Half of MS Patients Treated With T... [Published PT Community - 5 hours ago]
Research and Markets: China Diabetes Management... [Published CNBC - 5 hours ago]
Obituary: J. Donald Monsky [Published Sarasota Observer - 6 hours ago]
Puma Biotech Surges on Positive Results on Nera... [Published Yahoo! Finance - 6 hours ago]
Puma Biotech up more than 270% in one day [Published Yahoo! News - 7 hours ago]
Another major drop in sales for GSK [Published Pharmafocus - 7 hours ago]
U.S. FDA approves Gilead's blood cancer drug Zy... [Published CNBC - 7 hours ago]
Statement from FDA Confirms Approval of Gilead'... [Published Benzinga.com - 8 hours ago]
China Insulin Delivery Devices Market 2006-2019 [Published Individual.com - 8 hours ago]
Ultragenyx Appoints CMO [Published Contract Pharma - 8 hours ago]
Pembrolizumab Works in Melanoma After Ipilimumab [Published American Journal of Public Health - 9 hours ago]
S&P rises to record, stocks mixed on earnings [Published CNBC - 10 hours ago]
Ultragenyx Appoints Sunil Agarwal, M.D. as Chie... [Published EMoneyDaily - 10 hours ago]
Branded and Targeted Treatments Driving Almost ... [Published Samedan Ltd Pharmaceutical Publishers - 11 hours ago]
Wednesday’s Top Health Care Stories: Puma, Biog... [Published Motley Fool - 11 hours ago]
Fury over West Wallsend tyre dumping [Published Newcastle Herald - 11 hours ago]
Code42 Named in Internet Retailer’s Prestigious... [Published EON: Enhanced Online News - 11 hours ago]
2 Great European ETFs to Buy in an Uncertain Ma... [Published Zacks.com - 12 hours ago]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
FDA grants Genentech’s Avastin priority review ... [Published PBR - News - 14 hours ago]
Genentech, a member of the Roche Group, has announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Avastin (bevacizumab) plus chemotherapy for ...
FDA Grants Genentech’s Avastin Priority Review ... [Published Business Wire Health News - Jul 22 2014]
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) ...
Research and Markets: Global Transcriptomics Ma... [Published Business Wire Manufacturing News - Jul 21 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/k632cr/global) has announced the addition of the "Global Transcriptomics Market 2014-2018" report to their offering. The Global Transcriptomics market will grow ...
Innovator Liability at 100 [Published Drug and Device Law - Jul 18 2014]
This post is only from the Reed Smith (more properly, the non-Dechert) side of the blog.One hundred what, you say?Certainly not years; the awful Conte v. Wyeth, Inc., 85 Cal. Rptr.3d 299, (Cal. App. 2008), decision just turned six – this blog is older ...
Who can you meet this year at Partnerships in C... [Published Partnerships in Clinical Trials - Jul 18 2014]
The 6th Annual Partnerships in Clinical Trials Asia at the Sheraton Shanghai Hongqiao, China on 16-18 September 2014 addresses the partnership opportunities in Asia, the critical challenges faced and solutions to ensure the success of Clinical Trials ...
1 2 3 4 5 6 7 8 9 10 ...

Audio/Video

sort by: Date | Relevance
Roche to pay $1.7bn for Seragon [Published Reuters Video: Business - Jul 02 2014]
1

Press Releases

sort by: Date | Relevance
OTC Markets Group Announces Second Quarter Perf... [Published OTC Markets Group Corporate News - Jul 17 2014]
Seragon Pharmaceuticals Announces Acquisition A... [Published GlobeNewswire: Acquisitions News - Jul 02 2014]
Curis Announces Investigational New Drug Applic... [Published GlobeNewswire: Building News - Jun 23 2014]
Ventana Medical Systems, Inc. and MedImmune col... [Published Financial Services - Jun 04 2014]
Curis Announces Abstracts for Its Partnered Pro... [Published GlobeNewswire: Acquisitions News - May 23 2014]
1 2 3 4
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.